Literature DB >> 2724117

Reversal of glare disability after cataract surgery.

S Masket.   

Abstract

Awareness of the limitations of Snellen vision testing and the favorable risk-to-benefit ratio for cataract surgery have changed the indications for cataract rehabilitation. Interest in functional vision analysis generated the present study, which was designed to identify cataract-specific disabling glare and its reversal with best-case cataract surgical techniques. Thirty eyes with symptomatic cataracts and no other ocular diseases were evaluated by Miller-Nadler glare testing prior to and six weeks after surgery. All surgical cases were uncomplicated and were free of macular disease. They had well-centered posterior chamber intraocular lenses, clean posterior capsules, and were returned to 20/20 Snellen acuity. Careful patient selection assured that presurgical glare disability was due to cataract formation. Presurgical Miller-Nadler scores were markedly elevated and correlated well with symptomatic glare, whereas postoperative scores were indistinguishable from normals, suggesting that cataract-induced symptomatic glare is discernible, remediable, and warrants surgical intervention, but requires best-case surgery to assure glare reversal.

Entities:  

Mesh:

Year:  1989        PMID: 2724117     DOI: 10.1016/s0886-3350(89)80005-7

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  3 in total

Review 1.  Management of cataract.

Authors:  R Dickson; A Eastwood; P Gill; A Melville; S O'Meara; T Sheldon
Journal:  Qual Health Care       Date:  1996-09

2.  Visual impairment, visual functioning, and quality of life assessments in patients with glaucoma.

Authors:  R K Parrish
Journal:  Trans Am Ophthalmol Soc       Date:  1996

3.  Correlation between higher-order aberration and photophobia after cataract surgery.

Authors:  Naoko Ishiguro; Hiroshi Horiguchi; Satoshi Katagiri; Takuya Shiba; Tadashi Nakano
Journal:  PLoS One       Date:  2022-09-15       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.